Oxford Pharmascience Group

Oxford Pharmascience is a drug development company that re-develops approved drugs using proprietary formulation technologies to make them better, safer and easier to take. Since Oxford Pharmascience's products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market. The Company's pipeline is focused on cardiovascular disease and pain relief indications addressing unmet patient needs with significant commercial potential in global markets. The company was founded in February'08 and floated in London's AIM market in February 2010.
Company Growth (employees)
Type
Public
HQ
London, GB
Founded
2008
Size (employees)
10 (est)
Oxford Pharmascience Group was founded in 2008 and is headquartered in London, GB

Oxford Pharmascience Group Office Locations

Oxford Pharmascience Group has an office in London
London, GB (HQ)
2 Royal College Street, Camden

Oxford Pharmascience Group Metrics

Oxford Pharmascience Group Financial Metrics

Revenue (2015)

£749 k

Revenue growth (2014-15), %

6%

Gross profit

£158 k

Gross profit margin (2015), %

21%

Market capitalization (26-May-2015)

$253.2 b

Closing share price (26-May-2015)

$0.2
Oxford Pharmascience Group's current market capitalization is $253.2 b.
Oxford Pharmascience Group's revenue was reported to be £749 k in FY, 2015 which is a 6.2% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

£1 m£705 k£749 k

Revenue growth, %

(31%)6%

Cost of goods sold

£693 k£482 k£591 k

Gross profit

£336 k£223 k£158 k

Gross profit Margin, %

33%32%21%

Operating expense total

£1.9 m£3.7 m£4.1 m

Oxford Pharmascience Group Company Life

You may also be interested in